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Abstract
Background: To assess heart failure therapies in diabetic patients with preserved as compared to impaired systolic
ventricular function.
Methods: 3304 patients with heart failure from 9 different studies were included (mean age 63 ± 14 years); out of
these, 711 subjects had preserved left ventricular ejection fraction (≥ 50%) and 994 patients in the whole cohort
suffered from diabetes.
Results: The majority (>90%) of heart failure patients with reduced ejection fraction (SHF) and diabetes were
treated with an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) or with beta-blockers. By contrast,
patients with diabetes and preserved ejection fraction (HFNEF) were less likely to receive these substance classes (p
< 0.001) and had a worse blood pressure control (p < 0.001). In comparison to patients without diabetes, the
probability to receive these therapies was increased in diabetic HFNEF patients (p < 0.001), but not in diabetic SHF
patients. Aldosterone receptor blockers were given more often to diabetic patients with reduced ejection fraction
(p < 0.001), and the presence and severity of diabetes decreased the probability to receive this substance class,
irrespective of renal function.
Conclusions: Diabetic patients with HFNEF received less heart failure medication and showed a poorer control of
blood pressure as compared to diabetic patients with SHF. SHF patients with diabetes were less likely to receive
aldosterone receptor blocker therapy, irrespective of renal function.
Background
Heart failure is a major public health burden and the
lifetime risk of developing heart failure in a 40 year old
is around 20% [1]. About 50% of patients presenting
with heart failure have normal ejection fraction
(HFNEF) [2,3]. Recent research revealed that mortality
of hospitalized patients with HFNEF is comparable to
patients with systolic heart failure (SHF). However, in
most heart failure trials, HFNEF patients were largely
underrepresented.
Diabetes is a growing epidemiological burden and a
major contributor to cardiovascular disease. In male
patients with diabetes, the risk to develop heart failure
is doubled in comparison to non-diabetic patients, but it
is five times the risk of non-diabetic patients in women
[4]. Moreover, diabetes is an independent predictor of
poor outcome once SHF or HFNEF have developed
[5,6]. Current treatment guidelines provide evidence for
pharmacotherapy in diabetic patients with heart failure
and adherence to guidelines is associated with improved
outcome in both types of heart failure [7,8]. Of note, the
fore-mentioned guideline does not specifically address
patients with HFNEF [7].
The aim of the present study was to compare heart fail-
ure therapy in diabetic patients with SHF and HFNEF.
Methods
Patient cohorts
All subjects recruited within the German Heart Failure
Network are characterized by an extensive standardizes
baseline data set including information on socio-
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demographics, physical examination, heart failure aetiol-
ogy and classification, cardiovascular risk factors,
comorbidities, medication, ECG, echocardiography, cor-
onary angiography, routine laboratory, and quality of life
[9]. In all studies, a uniform baseline data set was
obtained. All diagnostic procedures were performed in
accordance with pre-specified Standard Operating Pro-
cedures. All individual studies were approved by local
ethics committees.
For the current analysis, all patients from prospective
follow-up studies with a diagnosis of heart failure were
eligible.
In all patients echocardiography was performed
according to guidelines of the American Society of
Echocardiography (ASE) current at the time of data col-
lection, including targeted M-Mode and Doppler techni-
ques. All examinations were performed by physicians
experienced in the technique and a pre-specified stan-
dard operation procedure regarding echocardiography
was given. Preferable, the left ventricular ejection frac-
tion was determined using the Simpson’s model of discs.
If patient’s constitution did not allow sufficient appli-
ance of the Simpson’s method, visual estimation of
LVEF was permitted too. Patients were classified as hav-
ing SHF or HFNEF by echocardiographically determined
left ventricular ejection fraction using a cut-off of 50%.
Glomerular filtration rate was calculated by MDRD
formula [10].
Statistics
Data are presented as mean+/-SD or percentages. Esti-
mates of percent of patients receiving a certain substance
class are provided with 95% confidence intervals (CI).
Data were analysed by analysis of variance (quantita-
tive) and logistic regression (frequencies), both including
interaction terms for diabetes and left ventricular func-
tion. A two-tailed p < 0.05 was considered statistical sig-
nificant. SPSS 15 (SPSS Inc., Chicago, IL) was used for
analysis.
All individual studies were approved by local ethics
committees. The authors had full access to and take full
responsibility for the integrity of the data.
Results
Patient characteristics
3304 patients with heart failure from nine different sub-
studies were included into this analysis. In the total
sample, 711 patients (22%, 353 women) had preserved
ejection fraction and 2593 patients (78%, 653 women)
had SHF. 2310 patients (70%) were free of diabetes, 622
(19%) had mild diabetes (treated by diet or oral anti-
hyperglycemic drugs) and 372 (11%) had severe diabetes
(insulin-dependent treatment). Baseline characteristics of
the study cohort are also displayed in table 1, showing
significant differences for most variables according to
presence of diabetes or SHF. Except for the SF-36 score,
no significant interaction of effects of diabetes and ejec-
tion fraction was seen on all baseline variables.
Treatment
Overall, a high percentage of patients received the class
I recommended therapy (i.e., angiotensin converting
enzyme inhibitors [ACEi] or angiotensin-2 receptor-1
blocker [ARB] and beta-blockers). However, differences
were observed between HFNEF and SHF patients. Blood
pressure control in HFNEF was poorer than in SHF,
and was poorer in patients with diabetes than in
patients without diabetes (see table 1). There were also
differences how guideline-recommended substance
classes were applied in SHF and HFNEF for three
important sub-groups: Patients free of diabetes, patients
with mild diabetes and patients with severe diabetes [7].
As displayed in figure 1 around 90% of patients with
SHF received ACEi or ARB (panel A) and beta-blockers
(panel B) and neither the presence nor the severity
affected the treatment with these substance classes (p =
0.409 and p = 0.724, respectively). By contrast, the
intake of diuretics (figure 2, panel A) increased with the
presence and severity of diabetes (p < 0.001, respec-
tively) and a reduction in aldosterone receptor blocker
usage with diabetes (Figure 2, panel B) was observed
(p < 0.001).
As shown in figure 1, in HFNEF fewer patients
received ACEi/ARB therapy than in SHF (p < 0.001).
However, in contrast to SHF, both presence and the
severity of diabetes were associated with a higher intake
frequency of these substance classes (p < 0.001). A simi-
lar pattern was seen for beta-blockers (figure 1): The
intake in HFNEF was reduced, but increased with the
presence and severity of diabetes (p = 0.014). The pre-
sence of CAD was associated with a higher intake fre-
quency of beta-blockers in HFNEF, but not in SHF.
Comparable to SHF, diuretic therapy (figure 2) increased
with the presence and severity of diabetes (p < 0.001).
As also shown in figure 2, aldosterone receptor blockers
were administered with lower frequency in HFNEF (p <
0.001); this association was unaffected by the presence
and severity of diabetes (p = 0.198).
Role of comorbidities
We investigated in detail the associations between renal
dysfunction and the intake frequency of aldosterone
receptor blockers, since hyperkalemia due to spironolac-
tone poses a relevant risk in heart failure therapy [11].
Glomerular filtration rate was lower in SHF than in
HFNEF and lower in diabetic than in non-diabetic
patients and was lower in diabetic SHF than in diabetics
HFNEF patients (see table 1). Figure 3 shows the
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treatment frequency of aldosterone receptor blockers
stratified by preserved or reduced renal function and
type of heart failure. In SHF, the percentage of
patients receiving aldosterone receptor blockers
decreased with the presence and severity of diabetes.
Interestingly, this tendency was similar in patients
with reduced and preserved renal function. Moreover,
serum potassium levels were not different in patients
without and with diabetes (p = 0.756 for HFNEF, p =
0.162 for SHF).
In the whole sample, the intake of ACEi/ARB was
independently associated with the presence of diabetes,
hypertension and renal dysfunction. In contrast, the
intake of beta-blockers was associated with the presence
of coronary artery disease and hypertension.
Discussion
This is the first study to evaluate the most recent ESC/
EASD recommendations for heart failure therapy in a
large contemporary cohort of patients with heart failure.
Moreover, no previous paper has studied a comparably
high number of diabetic patients with heart failure and
normal ejection fraction (HFNEF).
Our study has three major findings:
(1) Around 90% of diabetic patients with SHF are
treated with ACEi/ARB and beta-blockers. This ther-
apy pattern is not different from patients without
diabetes.
(2) In contrast, diabetic patients with HFNEF are
less likely to receive ACEi/ARB and beta-blockers.
However, as compared to non-diabetic patients, they
are more likely to receive these therapies. Blood
pressure control in diabetic HFNEF patients is
poorer than in diabetic SHF patients.
(3) Irrespective of renal function, diabetic SHF
patients are less likely to receive aldosterone
antagonists.
Heart failure therapy in surveys
The percentage of patients with SHF receiving ACEi/
ARB and betablockers was close to 90% and, hence,
much higher than reported in previous surveys (e. g.,
the EuroHeart Survey) [12]. The large proportion of uni-
versity centres and the exclusive recruitment in cardiol-
ogy clinics may be an explanation [13]. An additional
possibility is that slowly but steadily we reach a better
implementation of guidelines in Germany.
Heart failure therapy in patients with diabetes
There are very few, if any, clinical trials on heart failure
treatment available that specifically address heart failure
with the comorbidity diabetes. Therefore, recent recom-
mendations carry a low level of evidence (level C) and
are derived from subgroup analyses of patients suffering
from diabetes in large heart failure trials [7]. In patients
with SHF, the use of ACEi/ARB, beta-blockers and
aldosterone antagonists have been shown to reduce
morbidity and mortality (for review, see [1]). Aldoster-
one antagonists reduce mortality in heart failure patients
with reduced ejection fraction and are of benefit in
patients with systolic heart failure and recent myocardial
infarction, with or without concomitant diabetes [14-16].
For HFNEF, there is yet no evidence-based drug-speci-
fic mortality reducing therapy available. Three trials
investigated the use of ACEi and ARBs in HFNEF
patients and failed to show a reduction in mortality
[17-19]. Other treatment strategies, e.g. aldosterone
receptor blockade, are currently investigated in clinical
trials. Tight blood pressure control is the only
Table 1 Baseline characteristics
No Diabetes (n = 2310) Diabetes (n = 994) P value for
respective effect
DM EF
EF <50% (n = 1769) EF ≥ 50% (n = 541) EF <50% (n = 824) EF ≥ 50% (n = 170)
Female (%) 23.5 49.2 28.9 51.2 0.005 <0.001
Age (years) 61.1 ± 14.3 63.1 ± 14.0 67.2 ± 10.3 69.4 ± 7.6 <0.001 <0.001
Body mass index (kg/m2) 26.9 ± 4.5 28.5 ± 5.1 29.1 ± 5.5 30.3 ± 5.3 <0.001 <0.001
Heart rate (bpm) 73.0 ± 13.5 69.7 ± 12.7 74.2 ± 12.5 72.4 ± 14.4 0.004 <0.001
Systolic blood pressure (mmHg) 121 ± 19 138 ± 23 125 ± 19 140 ± 21 <0.001 <0.001
Diastolic blood pressure (mmHg) 73 ± 11 79 ± 12 73 ± 11 77 ± 13 0.076 <0.001
Glomerular filtration rate (mL/min) 72 ± 24 75 ± 22 64 ± 26 68 ± 24 <0.001 0.002
Hb (mmol/mL) 8.7 ± 1.1 8.7 ± 1.0 8.4 ± 1.2 8.3 ± 1.1 <0.001 0.644
SF-36 score 52 ± 28 59 ± 28 44 ± 28 44 ± 27 <0.001 0.020*
*Significant interaction (p = 0.015) between diabetes and ejection fraction.
•DM: Diabetes mellitus, EF: ejection fraction.
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recommendation supported by evidence in HFNEF, thus
one would expect that this only recommendation would
be strictly followed. However, our study shows that
blood pressure control in HFNEF was inferior to SHF,
the difference of about 15 mmHg in systolic blood pres-
sure is partly explained by less pharmacotherapy.
The lack of evidence for heart failure treatment in
HFNEF might explain the lower use of ACEi/ARBs,
beta-blockers and aldosterone receptor blockers in
patients with HFNEF. In contrast, data from the
CHARM trial which was the largest trial to include
patients with both SHF and HFNEF, showed that the
presence of diabetes was of greater harm in HFNEF
than in SHF patients [20]. It is unknown whether a
more aggressive antihypertensive therapy develops bene-
fit in patients with HFNEF, but it has been shown that
diastolic dysfunction, a relevant pathophysiology in
HFNEF, is improved by lowering blood pressure [21].
We were recently able to show that diastolic dysfunction
is impaired along the whole diabetic continuum [22].
Furthermore, diastolic dysfunction, which is believed to
be the responsible mechanism for the development of
heart failure in the majority of patients with HFNEF, is
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Figure 1 Percentage of patients without diabetes (DM-), with mild diabetes (DM+, on diet or taking oral anti-hyperglycaemic drugs)
and with severe diabetes (DM++, insulin-dependent diabetes) receiving different drugs (mean, 95% confidence interval). Panel A
shows prevalence of treatment with ACE inhibitors or angiotensin receptor blockers, panel B shows therapy with beta-blockers. Data are
separated by ejection fraction: Left side preserved ejection fraction (EF ≥ 50%), right side reduced ejection fraction (EF <50%).
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[23]. This increase in frequency of diastolic dysfunction
in diabetes mellitus is thereby independent of renal
function and can also be found under effective glycae-
mic control [24,25]. Given the proposed association of
diabetes mellitus and blood pressure control with dia-
stolic dysfunction, we argue for an improvement of anti-
hypertensive therapy and of glycaemic control in
patients with HFNEF. However, the hypothesis that
strict blood pressure and glycaemic control is beneficial
in diabetic HFNEF patients should be tested in a pro-
spective randomised trial.
Role of comorbidities
The use of ACEi/ARB or spironolactone may cause
hyperkalemia, especially in patients with impaired renal
function. A large population-based study from Ontario
showed an increased incidence of hyperkalemia and sub-
sequent mortality after the publication of the RALES
trial and the rate of hyperkalemia in real-world is
thought to be much higher than in clinical trials for var-
ious reasons (e. g. less frequent assessment of electro-
lytes and renal function, higher dosage of medication)
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Figure 2 Percentage of patients without diabetes (DM-), with mild diabetes (DM+, on diet or taking oral anti-hyperglycaemic drugs)
and with severe diabetes (DM++, insulin-dependent diabetes) receiving different drugs (mean, 95% confidence interval). Panel A
shows prevalence of treatment with diuretics, panel B shows therapy with aldosterone receptor blockers. Data are separated by ejection fraction:
Left side preserved ejection fraction (EF ≥ 50%), right side reduced ejection fraction (EF <50%).
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shown to be an independent risk factor for the develop-
ment of hyperkalemia and severe hyperkalemia (asso-
ciated with hospitalization or death) [28,29]. Even with
impaired renal function, however, heart failure patients
with diabetes will benefit from ARB therapy and aldos-
terone receptor blockade, similarly to patients without
diabetes [28,29]. Our data from a clinical practice setting
suggest that the presence of the heart failure comorbid-
ity diabetes restrains doctors from prescribing evidence-
based therapy in heart failure patients - possibly in fear
of side-effects, although these side-effects can be easily
monitored by simple blood tests. As a consequence, we
suggest that diabetic heart failure patients should receive
appropriate doses of ACEi/ARB and/or aldosterone
receptor blockers under a tight control of potassium
and renal function markers, rather than withholding
these potentially life-saving drugs. Moreover, future
heart failure trials should focus on common comorbid-
ities in heart failure populations (diabetes, impaired
renal function, high age).
Limitations
This is a cross-sectional observational study and
although we included a high number of diabetic patients
with HFNEF, the majority of included diabetic patients
had SHF. In some of the studies, only patients with SHF
were included. Thus, a stricter guideline-adherence for
SHF in these SHF only studies may be an alternative
explanation for the observed differences to HFNEF ther-
apy. LVEF was not measured using a uniform methodol-
ogy and intra- and inter-observer variability was not
investigated and compared between the several medical
centres. Although in most of all included patients LVEF
was calculated according to Simpson’s method, this may
have biased our results.
Although we controlled for estimated glomerular fil-
tration rate, we cannot rule out that more patients with
diabetes had a history of acute renal failure and this
could partly explain the lower frequency of aldosterone
receptor intake in these patients.
Conclusions
Despite significant improvements in the pharmacother-
apy of heart failure, there is still a considerable under-
treatment in diabetic heart failure patients with HFNEF.
Diabetic SHF patients are less likely to receive aldoster-
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Figure 3 Percentage of patients without diabetes (DM-), with mild diabetes (DM+) and with severe diabetes (DM++) receiving
aldosterone receptor blockade therapy. On the left panel, results are shown for patients with preserved renal function (GFR >60 ml/min), and
on the right panel for patients with reduced renal function.
Edelmann et al. Cardiovascular Diabetology 2011, 10:15
http://www.cardiab.com/content/10/1/15
Page 6 of 8
Acknowledgements
This work was supported by grants from the German Federal Ministry of
Education and Research (German Competence Network Heart Failure, TP 7
(FKZ 01GI0205), clinical trial program Aldo-DHF (FKZ 01KG0506)) and the
German Diabetes Foundation.
Author details
1Department of Cardiology and Pneumology, University of Göttingen,
Göttingen, Germany. 2Department of Cardiology, Campus Virchow, Charité
University, Berlin, Germany. 3Medical Clinic and Policlinic I, University of
Würzburg, Würzburg, Germany. 4Clinic for Internal Medicine and Cardiology,
University of Marburg, Marburg, Germany. 5Department of Cardiology,
University Duisburg-Essen, Germany. 6Clinical Trial Center, University of
Leipzig, Leipzig, Germany. 7Department of Cardiology, Medical University of
Graz, Graz, Austria.
Authors’ contributions
FE and RW participated in the design and the coordination of the study.
They also participated in the acquisition of data throughout the study, in
the analyses and interpretation of the results and drafted the manuscript. H-
DD, SS, AR, RS, TN, CL, CEA and FM participated in the design of the study
as well as in the acquisition of data throughout the study and were
integrated in the analyses and interpretation of the results. GG participated
in the design of the study and all aspects related to biometry. He has the
full responsibility of the integrity of the data and the results. BP participated
in the design and coordination of the study and helped to draft the
manuscript. All authors critically read, revised and approved the final
manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 13 December 2010 Accepted: 8 February 2011
Published: 8 February 2011
References
1. Lloyd-Jones DM, Larson MG, Leip EP, Beiser A, D’Agostino RB, Kannel WB,
Murabito JM, Vasan RS, Benjamin EJ, Levy D, Framingham Heart Study:
Lifetime risk for developing congestive heart failure: The Framingham
Heart Study. Circulation 2002, 106:3068-3072.
2. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM:
Trends in prevalence and outcome of heart failure with preserved
ejection fraction. N Engl J Med 2006, 355:251-9.
3. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, Gong Y, Liu PP:
Outcome of heart failure with preserved ejection fraction in a
population-based study. N Engl J Med 2006, 355:260-9.
4. Kannel WB, Hjortland M, Castelli WP: Role of diabetes in congestive heart
failure: the Framingham study. Am J Cardiol 1974, 34:29-34.
5. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJ, Swedberg KB,
Ostergren J, Michelson EL, Pieper KS, Granger CB: Predictors of mortality
and morbidity in patients with chronic heart failure. Eur Heart J 2006,
27:65-75.
6. Tribouilloy C, Rusinaru D, Mahjoub H, Tartiere JM, Kesri-Tartiere L, Godard S,
Peltier M: Prognostic impact of diabetes mellitus in patients with heart
failure and preserved ejection fraction. A prospective 5-year study. Heart
2008, 94:1450-5.
7. Ryden L, Standl E, Bartnik M, van den Berghe G, Betteridge J, de Boer MJ,
Cosentino F, Jönsson B, Laakso M, Malmberg K, Priori S, Östergren J,
Tuomilehto J, Thrainsdottir I: Guidelines on diabetes, pre-diabetes, and
cardiovascular diseases. Eur Heart J 2007, 28:88-136.
8. Störk S, Hense HW, Zentgraf C, Uebelacker I, Jahns R, Ertl G, Angermann CE:
Pharmacotherapy according to treatment guidelines is associated with
lower mortality in a community-based sample of patients with chronic
heart failure. A prospective cohort study. Eur J Heart Fail 2008, 10:1236-45.
9. Mehrhof F, Löffler M, Gelbrich G, Özcelik C, Posch M, Hense HW, Keil U,
Scheffold T, Schunkert H, Angermann C, Ertl G, Jahns R, Pieske B, Wachter R,
Edelmann F, Wollert K, Maisch B, Pankuweit S, Erbel R, Neumann T,
Herzog W, Katus H, Müller-Tasch T, Zugck C, Düngen HD, Regitz-Zagrosek V,
Lehmkuhl E, Störk S, Siebert U, Wasem J, Neumann A, Göhler A, Anker SD,
Köhler F, Möckel M, Osterziel KJ, Dietz R, Rauchhaus M, on behalf of the
Competence Network Heart Failure: A network against failing hearts -
introducing the German “Competence Network Heart Failure”. Int J
Cardiol 2010, 145:135-8.
10. National Kidney Foundation: K/DOQI clinical practice guidelines for
chronic kidney disease: evaluation, classification, and stratification. Am J
Kidney Dis 2002, 39:S1-266.
11. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A,
Redelmeier DA: Rates of hyperkalemia after publication of the
randomized Aldactone Evaluation Study. N Engl J Med 2004, 351:543-551.
12. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A,
Dietz R, Gavazzi A, van Gilst WH, Hobbs R, Korewicki J, Madeira HC,
Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J, the
study group of diagnosis of the working group on heart failure of the
European Society of Cardiology: EuroHeart Failure Survey programme - a
survey on the quality of care among patients with heart failure in
Europe. Part 2: treatment. Eur Heart J 2003, 24:464-474.
13. Taubert G, Bergmeier C, Andresen H, Senges J, Potratz J: Clinical profile
and management of heart failure: rural community hospital vs.
metropolitan heart center. Eur J Heart Fail 2001, 3:611-617.
14. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J,
Wittes J, Randomized Aldosterone Evaluation Study Investigators: The effect
of spironolactone on morbidity and mortality in patients with severe
heart failure. N Engl J Med 1999, 341:709-717.
15. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R,
Hurley S, Kleiman J, Gatlin M, Eplerenone post-acute myocardial infarction
heart failure efficacy and survival study investigators: Eplerenone, a
selective aldosterone receptor blocker, in patients with left ventricular
dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
16. O’Keefe JH, Abuissa H, Pitt B: Eplerenone improves prognosis in
postmyocardial infarction diabetic patients with heart failure: results
from EPHESUS. Diabetes Obes Metab 2008, 10:492-497.
17. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J, PEP-
CHF Investigators: The perindopril in elderly people with chronic heart
failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
18. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ,
Michelson EL, Olofsson B, Ostergren J, CHARM Investigators and
Committees: Effects of candesartan in patients with chronic heart failure
and preserved left-ventricular ejection fraction: the CHARM-Preserved
trial. Lancet 2003, 362:777-781.
19. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR,
Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A, the I-PRESERVE
Investigators: Irbesartan in patients with heart failure and preserved
ejection fraction. N Engl J Med 2008, 359:2456-67.
20. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB,
Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ,
CHARM Investigators: Impact of diabetes on outcomes in patients with
low and preserved ejection fraction heart failure: an analysis of the
Candesartan in Heart failure: Assessment of reduction in mortality and
morbidity (CHARM) programme. Eur Heart J 2008, 29:1377-1385.
21. Solomon SD, Janardhanan R, Verma A, Bourgoun M, Daley WL, Purkayastha D,
Lacourcière Y, Hippler SE, Fields H, Naqvi TZ, Mulvagh SL, Arnold JM,
Thomas JD, Zile MR, Aurigemma GP, Valsartan In Diastolic Dysfunction
(VALIDD) Investigators: Effect of angiotensin receptor blockade and
antihypertensive drugs on diastolic function in patients with hypertension
and diastolic dysfunction: a randomised trial. Lancet 2007, 369:2079-2087.
22. Stahrenberg R, Edelmann F, Mende M, Kockskämper A, Düngen HD,
Scherer M, Kochen MM, Binder L, Herrmann-Lingen C, Gbiorczyk J,
Gelbrich G, Hasenfuß G, Pieske B, Wachter R: Association of glucose
metabolism with diastolic function along the diabetic continuum.
Diabetologia 2010, 53:1331-40.
23. Romano S, Di Mauro M, Fratini S, Guarracini L, Guarracini F, Poccia G, Penco M:
Early diagnosis of left ventricular diastolic dysfunction in diabetic patients:
a possible role for natriuretic peptides. Cardiovasc Diabetol 2010, 9:89.
24. Nardi E, Palermo A, Mulè G, Cusimano P, Cottone S, Cerasola G: Impact of
type 2 diabetes on left ventricular geometry and diastolic function in
hypertensive patients with chronic kidney disease. J Hum Hypertens 2010.
25. Poantă L, Fodor D, Albu A: Left ventricular function in patients with
uncomplicated well-controlled diabetes mellitus. Med Ultrason 2010,
12:184-7.
26. Bozkurt B, Agoston I, Knowlton AA: Complications of inappropriate use of
spironolactone in heart failure: when an old medicine spirals out of new
guidelines. J Am Coll Cardiol 2003, 41:211-214.
Edelmann et al. Cardiovascular Diabetology 2011, 10:15
http://www.cardiab.com/content/10/1/15
Page 7 of 8
27. Vanpee D, Swine CH: Elderly heart failure patients with drug-induced
serious hyperkalemia. Aging (Milano) 2000, 12:315-319.
28. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R, EPHESUS Investigators:
Serum potassium and clinical outcomes in the Eplerenone Post-Acute
Myocardial Infarction Heart Failure Efficacy and Survival Study
(EPHESUS). Circulation 2008, 118:1643-1650.
29. Desai AS, Swedberg K, McMurray JJ, Granger CB, Yusuf S, Young JB,
Dunlap ME, Solomon SD, Hainer JW, Olofsson B, Michelson EL, Pfeffer MA,
CHARM Program Investigators: Incidence and predictors of hyperkalemia
in patients with heart failure: an analysis of the CHARM Program. J Am
Coll Cardiol 2007, 50:1959-1966.
doi:10.1186/1475-2840-10-15
Cite this article as: Edelmann et al.: Heart failure therapy in diabetic
patients-comparison with the recent ESC/EASD guideline. Cardiovascular
Diabetology 2011 10:15.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Edelmann et al. Cardiovascular Diabetology 2011, 10:15
http://www.cardiab.com/content/10/1/15
Page 8 of 8
